Pulse Explore Journal Club Debates Trending Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease | Synapse

March 14, 2024

View Full Paper

Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease

HNHai V. NguyenCentre for Quantum Technologies SMShweta MitalUniversity of Manitoba

David S. KnopmanKarlsruhe Institute of Technology

Key Points

Key points are not available for this paper at this time.

Abstract

Little is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). This study aims to quantify the cost-effectiveness of lecanemab and how it varies based on the accuracy of AD testing and individuals'

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Nguyen et al. (Thu,) studied this question.

synapsesocial.com/papers/68e73fdcb6db6435876b951b https://doi.org/https://doi.org/10.1212/wnl.0000000000209218